正邦科技(002157.SZ):4月生豬銷售收入環比降21.60%、同比降74.67%
格隆匯5月9日丨正邦科技(002157.SZ)公佈2022年4月份生豬銷售情況簡報,公司2022年4月銷售生豬91.86萬頭(其中仔豬30.35萬頭,商品豬61.51萬頭),環比下降5.03%,同比下降22.45%;銷售收入7.69億元,環比下降21.60%,同比下降74.67%。
商品豬(扣除仔豬後)銷售均價12.43元/公斤,較上月增長10.01%;均重86.96公斤/頭,較上月下降16.09%。
2022年1-4月,公司累計銷售生豬334.47萬頭,同比下降11.12%;累計銷售收入35.50億元,同比下降67.84%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.